When Julie was diagnosed with advanced medullary thyroid cancer in 2020, she thought she only had a year to live. Her family, including her three children were devastated. After being referred to The Royal Marsden and meeting Dr Newbold, Consultant Clinical Oncologist, she felt reassured for the first time.
Julie was given the opportunity to join the LIBRETTO-531 clinical trial, which uses a new treatment called Selpercatinib. This drug targets the abnormally activated pathways in the thyroid cancer cell when there is a mutation in a specific gene.
Remarkably, by July 2022, Julie's tumours had shrunk by almost 77%.
I am so thankful to still be here, able to spend time with my three children and make more beautiful memories. I’ve been given more time than I ever imagined – there really is no greater gift.
Please donate now and support life-changing research to give more people, like Julie, and their families, hope for the future.
Your generosity allows The Royal Marsden Cancer Charity to support the Royal Marsden in continuing to trial new drugs and improve existing treatments, to transform and save the lives of people with cancer across the UK and around the world.